Targeting non-muscle myosin II inhibits proliferative vitreoretinopathy through regulating epithelial-mesenchymal transition
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.149149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Haiping Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China; Institute for …. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research, National Natural Science Foundation of China.
Abstract (Originalsprache)
Proliferative vitreoretinopathy (PVR) is a common complication of rhegmatogenous retinal detachment, eventually leading to vision loss. To date, there are no effective drugs for the treatment of this disease. In this study, we investigated the effect of blebbistatin, a non-muscle myosin II inhibitor, on the ARPE-19 cell line and in a rabbit model of proliferative vitreoretinopathy. In vitro, we found that blebbistatin inhibited the epithelial-mesenchymal transition of retinal pigment epithelial (RPE) cells and inhibited the ability of RPE cells to migrate, proliferate, generate extracellular matrix, and affect contractility. In vivo the PVR model showed that blebbistatin significantly delayed PVR progression. It also partially prevents the loss of retinal function caused by PVR. Our results suggest that blebbistatin is a potential drug with clinical applications for the treatment of PVR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China; Institute for Stem Cell and Regenerative Medicine, Chinese Academy of Sciences, Beij…
- Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory…
Förderung
- National Key Research and Development Program of China
- National Key Research and Development Program of China Stem Cell and Translational Research
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- Capital Health Research and Development of Special Fund
Zitieren
APA
Jiang, H., Chen, Y., He, Z., Li, J., Gao, Q., Li, W., Wei, W., & Zhang, Y. (2023). Targeting non-muscle myosin II inhibits proliferative vitreoretinopathy through regulating epithelial-mesenchymal transition. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.149149
Vancouver
Jiang H, Chen Y, He Z, Li J, Gao Q, Li W, et al. Targeting non-muscle myosin II inhibits proliferative vitreoretinopathy through regulating epithelial-mesenchymal transition. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.149149
BibTeX
@article{Jiang2023,
author = {Jiang, Haiping and Chen, Yuning and He, Zhengquan and Li, Jie and Gao, Qingqin and Li, Wei and Wei, Wenbin and Zhang, Ying},
title = {Targeting non-muscle myosin II inhibits proliferative vitreoretinopathy through regulating epithelial-mesenchymal transition},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.149149}
}
EUVIMED